NCT05592418Phase 2Completed

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

Study sponsor: AIM ImmunoTech Inc. · AIM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-11-17Actual
Enrollment · participants80Actual
Source updated2025-01-22Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview